AMGN

Amgen Inc.

September 22, 2026 · pre-market

Rarity

1.56

Peak move

+4.85%

Float cap

$211.5B

Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines for serious diseases. It focuses on areas of high unmet medical need and operates in one segment: human therapeutics. The company sells these medicines to patients in approximately 100 countries, with sales and marketing concentrated in the United States and Europe.

• analyst_ratingSep 22 · 07:27 ET

  Erste Group Bank analyst H. Engel cut Amgen's FY2027 EPS estimate to $24.36 from $24.43 in a September 18 research note, against a $22.94 consensus.

  Webmarketbeat.com
• Key eventregulatory_actiontime: see source

  Britain's medicines regulator suspended the use and sale of Amgen's rare-disease drug Tavneos (avacopan) for new patients, saying the main study supporting its approval was unreliable.

  Webbackpack.exchange
• Key eventpatent_eventSep 21 · 19:43 ET

  Bristol-Myers Squibb and Ono Pharmaceutical sued Amgen in the US District Court for Delaware, alleging Amgen's proposed nivolumab biosimilar ABP 206 infringes seven Opdivo patents; the complaint was filed under seal Sept 8 and unsealed the following week.

  Webwebiis08.mondaq.comWebthepharmaletter.comWebbigmoleculewatch.com
• Key eventexecutive_remarkSep 21

  Amgen chief medical officer Paul Burton said in a Seoul interview that AI has cut regulatory document preparation from six months to six weeks and predicted it will shorten total drug development time about 25% by the early 2030s.

  Webmk.co.kr
• institutional_flowSep 19 · 03:31 ET

  Nykredit A S disclosed a new position of 135,233 Amgen shares valued at approximately $49.0 million in its most recent Form 13F filing for the second quarter.

  Webmarketbeat.com
• analyst_ratingSep 18

  Morgan Stanley told clients that Amgen's olpasiran, which cuts Lp(a) 95%-99% in patients with Lp(a) of at least 200 nmol/L, differs from Novartis's failed pelacarsen, after meeting Amgen management at its healthcare conference on Sept 15.

  Webthestreet.com
• analyst_ratingSep 17

  BMO Capital maintained a Hold rating on Amgen with a $450 price target and Scotiabank maintained Buy with a $450 target on Sep 17, 2026.

  Webstockanalysis.com
• analyst_ratingSep 17

  UBS Group reiterated its Buy rating on Amgen on September 17, 2026.

  Webmarketbeat.com
• analyst_ratingSep 4

  Wells Fargo raised its Amgen price target to $435 from $400 while keeping an Equalweight rating.

  Webttm.financial
• major_contractAug 19

  TScan Therapeutics disclosed in an SEC filing that Amgen will terminate their research collaboration and license agreement.

  Webttm.financial